- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 2,553
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Arrhythmias
- Interventions
- azimilide dihydrochloride
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • La Jolla, California + 43 more
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 78
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- tucatinib, trastuzumab deruxtecan
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Alhambra, California + 92 more
- Conditions
- BK Polyomavirus, Kidney Diseases
- Interventions
- FK778
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 21
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Anastrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 33 Years to 96 Years · Female only
- Enrollment
- 4,172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more
- Conditions
- Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome
- Interventions
- Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion
- Drug
- Lead sponsor
- Elorac, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Duarte, California • Palo Alto, California + 11 more
- Conditions
- Asthma
- Interventions
- lebrikizumab, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 62
- States / cities
- Oxford, Alabama • Long Beach, California • Los Angeles, California + 57 more
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab 30 mg, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 126
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Anchorage, Alaska + 110 more
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma
- Interventions
- Biospecimen Collection, Computed Tomography, Questionnaire Administration, Thoracoscopy, Thoracotomy
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 50 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 220
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 142 more
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Interventions
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 365
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
- Interventions
- MRTX849, Pembrolizumab, Cetuximab, Afatinib
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more
- Conditions
- Prostate
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2020
- U.S. locations
- 6
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Lanham, Maryland + 2 more
- Conditions
- Tumor Pathway Activations Inhibited by Dovitinib
- Interventions
- Dovitinib (TKI258)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more
- Conditions
- Primary Pulmonary Hypertension
- Interventions
- LIQ861 Inhaled Treprostinil
- Drug
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
- Conditions
- Non Small Cell Lung Cancer, Solid Tumor
- Interventions
- BBP-398 with nivolumab
- Drug
- Lead sponsor
- Navire Pharma Inc., a BridgeBio company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Springdale, Arkansas • La Jolla, California • Santa Rosa, California + 11 more
- Conditions
- Advanced Solid Neoplasm
- Interventions
- Pevonedistat, Docetaxel, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Tampa, Florida • Detroit, Michigan + 5 more
- Conditions
- Aortic Valve Stenosis
- Interventions
- Portico transcatheter aortic valve, Commercially available transcatheter aortic valve
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 1,242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Concord, California + 56 more
- Conditions
- Colo-rectal Cancer, Cancer Colon, Cancer, Rectum, Neoplasms,Colorectal, Polyps, Polyp of Colon, Adenoma, Adenoma Colon
- Interventions
- Not listed
- Lead sponsor
- Freenome Holdings Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,275 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 29
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 25 more
- Conditions
- Atrial Fibrillation
- Interventions
- Cardioblate Surgical Ablation System, Surgical RF Ablation
- Device · Procedure
- Lead sponsor
- Medtronic Cardiac Surgery
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Concord, California • Los Angeles, California + 12 more
- Conditions
- Urothelial Cancer
- Interventions
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 19
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Taletrectinib, Placebo
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Pegylated liposomal doxorubicin, Carboplatin, trastuzumab
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 51 more